https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
0 (2007) to 26.2 (2017) days of therapy/1000 days at risk (p less then 0.001). Compared to pre-intervention, the estimated (post-intervention) reduction in FQ utilization was 28.4 (95% CI 10.9-46) days of therapy/1000 days at risk. Reduced FQ utilization was correlated with increase susceptibilities to ciprofloxacin of hospital onset isolates of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis (p less then 0.02), and Pseudomonas aeruginosa (p = 0.07). No significant susceptibility change was observed in the am
Like
Comment
Share
